Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept

Victor H. Gonzalez, David S. Boyer, Ursula Schmidt-Erfurth, Jeffrey S. Heier, Carmelina Gordon, Matthew S. Benz, Dennis M. Marcus, Nelson R. Sabates, Robert Vitti, Husain Kazmi, Alyson J. Berliner, Yuhwen Soo, Xiaoping Zhu, Hadi Moini, Oliver Zeitz, Rupert Sandbrink, Diana V. Do

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate retinal sensitivity in patients with diabetic macular edema who received intravitreal aflibercept injection (IAI) or laser. Methods: A substudy included 46 patients from DA VINCI (a randomized, double-masked Phase 2 study) receiving either laser, 0.5 mg IAI every 4 weeks, 2 mg IAI every 4 weeks, 2 mg IAI every 8 weeks after 3 monthly doses (2q8), or 2 mg IAI as-needed after 3 monthly doses for 52 weeks. Retinal sensitivity was measured in one (central), five (one central and four inner), and eight (four inner and four outer) optical coherence tomography subfields. Results: Mean best-corrected visual acuity improvement in the subgroup at Week 52 was 3.3 letters with laser and ranged from 5.4 to 16.3 letters in the IAI groups. Retinal sensitivity of laser patients at Week 52 was comparable with baseline in the central optical coherence tomography subfield but decreased in the five and eight optical coherence tomography subfields. Compared with laser, retinal sensitivity significantly increased with IAI in the 2q8 and pooled IAI groups in the 5 and 8 optical coherence tomography subfields at Week 52 (P <0.05). Conclusion: Intravitreal aflibercept injection improved best-corrected visual acuity and retinal sensitivity in this subgroup of patients. Laser may cause a deterioration of macular function that is not detectable with best-corrected visual acuity testing.

Original languageEnglish (US)
Pages (from-to)687-694
Number of pages8
JournalRetina
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Intravitreal Injections
Macular Edema
Lasers
Optical Coherence Tomography
Visual Acuity
aflibercept

Keywords

  • DA VINCI
  • DME
  • intravitreal aflibercept injection
  • laser
  • macular function
  • microperimetry
  • retinal sensitivity
  • VEGF Trap-Eye

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Gonzalez, V. H., Boyer, D. S., Schmidt-Erfurth, U., Heier, J. S., Gordon, C., Benz, M. S., ... Do, D. V. (2015). Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina, 35(4), 687-694. https://doi.org/10.1097/IAE.0000000000000430

Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. / Gonzalez, Victor H.; Boyer, David S.; Schmidt-Erfurth, Ursula; Heier, Jeffrey S.; Gordon, Carmelina; Benz, Matthew S.; Marcus, Dennis M.; Sabates, Nelson R.; Vitti, Robert; Kazmi, Husain; Berliner, Alyson J.; Soo, Yuhwen; Zhu, Xiaoping; Moini, Hadi; Zeitz, Oliver; Sandbrink, Rupert; Do, Diana V.

In: Retina, Vol. 35, No. 4, 01.04.2015, p. 687-694.

Research output: Contribution to journalArticle

Gonzalez, VH, Boyer, DS, Schmidt-Erfurth, U, Heier, JS, Gordon, C, Benz, MS, Marcus, DM, Sabates, NR, Vitti, R, Kazmi, H, Berliner, AJ, Soo, Y, Zhu, X, Moini, H, Zeitz, O, Sandbrink, R & Do, DV 2015, 'Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept', Retina, vol. 35, no. 4, pp. 687-694. https://doi.org/10.1097/IAE.0000000000000430
Gonzalez, Victor H. ; Boyer, David S. ; Schmidt-Erfurth, Ursula ; Heier, Jeffrey S. ; Gordon, Carmelina ; Benz, Matthew S. ; Marcus, Dennis M. ; Sabates, Nelson R. ; Vitti, Robert ; Kazmi, Husain ; Berliner, Alyson J. ; Soo, Yuhwen ; Zhu, Xiaoping ; Moini, Hadi ; Zeitz, Oliver ; Sandbrink, Rupert ; Do, Diana V. / Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. In: Retina. 2015 ; Vol. 35, No. 4. pp. 687-694.
@article{8221b5ffacf344c391b2611ef962e9c5,
title = "Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept",
abstract = "Purpose: To evaluate retinal sensitivity in patients with diabetic macular edema who received intravitreal aflibercept injection (IAI) or laser. Methods: A substudy included 46 patients from DA VINCI (a randomized, double-masked Phase 2 study) receiving either laser, 0.5 mg IAI every 4 weeks, 2 mg IAI every 4 weeks, 2 mg IAI every 8 weeks after 3 monthly doses (2q8), or 2 mg IAI as-needed after 3 monthly doses for 52 weeks. Retinal sensitivity was measured in one (central), five (one central and four inner), and eight (four inner and four outer) optical coherence tomography subfields. Results: Mean best-corrected visual acuity improvement in the subgroup at Week 52 was 3.3 letters with laser and ranged from 5.4 to 16.3 letters in the IAI groups. Retinal sensitivity of laser patients at Week 52 was comparable with baseline in the central optical coherence tomography subfield but decreased in the five and eight optical coherence tomography subfields. Compared with laser, retinal sensitivity significantly increased with IAI in the 2q8 and pooled IAI groups in the 5 and 8 optical coherence tomography subfields at Week 52 (P <0.05). Conclusion: Intravitreal aflibercept injection improved best-corrected visual acuity and retinal sensitivity in this subgroup of patients. Laser may cause a deterioration of macular function that is not detectable with best-corrected visual acuity testing.",
keywords = "DA VINCI, DME, intravitreal aflibercept injection, laser, macular function, microperimetry, retinal sensitivity, VEGF Trap-Eye",
author = "Gonzalez, {Victor H.} and Boyer, {David S.} and Ursula Schmidt-Erfurth and Heier, {Jeffrey S.} and Carmelina Gordon and Benz, {Matthew S.} and Marcus, {Dennis M.} and Sabates, {Nelson R.} and Robert Vitti and Husain Kazmi and Berliner, {Alyson J.} and Yuhwen Soo and Xiaoping Zhu and Hadi Moini and Oliver Zeitz and Rupert Sandbrink and Do, {Diana V.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1097/IAE.0000000000000430",
language = "English (US)",
volume = "35",
pages = "687--694",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept

AU - Gonzalez, Victor H.

AU - Boyer, David S.

AU - Schmidt-Erfurth, Ursula

AU - Heier, Jeffrey S.

AU - Gordon, Carmelina

AU - Benz, Matthew S.

AU - Marcus, Dennis M.

AU - Sabates, Nelson R.

AU - Vitti, Robert

AU - Kazmi, Husain

AU - Berliner, Alyson J.

AU - Soo, Yuhwen

AU - Zhu, Xiaoping

AU - Moini, Hadi

AU - Zeitz, Oliver

AU - Sandbrink, Rupert

AU - Do, Diana V.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose: To evaluate retinal sensitivity in patients with diabetic macular edema who received intravitreal aflibercept injection (IAI) or laser. Methods: A substudy included 46 patients from DA VINCI (a randomized, double-masked Phase 2 study) receiving either laser, 0.5 mg IAI every 4 weeks, 2 mg IAI every 4 weeks, 2 mg IAI every 8 weeks after 3 monthly doses (2q8), or 2 mg IAI as-needed after 3 monthly doses for 52 weeks. Retinal sensitivity was measured in one (central), five (one central and four inner), and eight (four inner and four outer) optical coherence tomography subfields. Results: Mean best-corrected visual acuity improvement in the subgroup at Week 52 was 3.3 letters with laser and ranged from 5.4 to 16.3 letters in the IAI groups. Retinal sensitivity of laser patients at Week 52 was comparable with baseline in the central optical coherence tomography subfield but decreased in the five and eight optical coherence tomography subfields. Compared with laser, retinal sensitivity significantly increased with IAI in the 2q8 and pooled IAI groups in the 5 and 8 optical coherence tomography subfields at Week 52 (P <0.05). Conclusion: Intravitreal aflibercept injection improved best-corrected visual acuity and retinal sensitivity in this subgroup of patients. Laser may cause a deterioration of macular function that is not detectable with best-corrected visual acuity testing.

AB - Purpose: To evaluate retinal sensitivity in patients with diabetic macular edema who received intravitreal aflibercept injection (IAI) or laser. Methods: A substudy included 46 patients from DA VINCI (a randomized, double-masked Phase 2 study) receiving either laser, 0.5 mg IAI every 4 weeks, 2 mg IAI every 4 weeks, 2 mg IAI every 8 weeks after 3 monthly doses (2q8), or 2 mg IAI as-needed after 3 monthly doses for 52 weeks. Retinal sensitivity was measured in one (central), five (one central and four inner), and eight (four inner and four outer) optical coherence tomography subfields. Results: Mean best-corrected visual acuity improvement in the subgroup at Week 52 was 3.3 letters with laser and ranged from 5.4 to 16.3 letters in the IAI groups. Retinal sensitivity of laser patients at Week 52 was comparable with baseline in the central optical coherence tomography subfield but decreased in the five and eight optical coherence tomography subfields. Compared with laser, retinal sensitivity significantly increased with IAI in the 2q8 and pooled IAI groups in the 5 and 8 optical coherence tomography subfields at Week 52 (P <0.05). Conclusion: Intravitreal aflibercept injection improved best-corrected visual acuity and retinal sensitivity in this subgroup of patients. Laser may cause a deterioration of macular function that is not detectable with best-corrected visual acuity testing.

KW - DA VINCI

KW - DME

KW - intravitreal aflibercept injection

KW - laser

KW - macular function

KW - microperimetry

KW - retinal sensitivity

KW - VEGF Trap-Eye

UR - http://www.scopus.com/inward/record.url?scp=84926229333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926229333&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000430

DO - 10.1097/IAE.0000000000000430

M3 - Article

C2 - 25621943

AN - SCOPUS:84926229333

VL - 35

SP - 687

EP - 694

JO - Retina

JF - Retina

SN - 0275-004X

IS - 4

ER -